The Clinical Observation Of Conbercept For The Treatment Of Retinal Vein Occlusion And Analysis Of Prognosis Of Visual Recovery

Objective To evaluate the clinical efficacy and safety of Conbercept intravitreal injection in patients with macular edema(ME)secondary to retinal vein occlusion(RVO)and to investigate the factors associated with long-term visual recovery.Methods 50 patients(50eyes)with RVO diagnosed by fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were enrolled in this study,including 16 CRVO(central retinal vein occlusion)(16eyes)and 34 BRVO(branch retinal vein occlusion)(34eyes).All patients received intravitreal injection of 0.05ml(10mg/ml)Conbercept,once per month.Further injection may be required if patients' follow-up indicated.The follow-up duration was six months.To analyze the best corrected visual acuity(BCVA)and central macular thickness(CMT)before and after treatment.Postoperative adverse reactions and complications were observed.The final visual gain(FVG)(converted into log MAR)were evaluated based on sex,age,duration,baseline BCVA,baseline CMT,and presence or absence of systemic diseases to identify the associated predictors of visual recovery.Results 1.Initial value:The sex,age,duration in CRVO and BRVO did not differ significantly between each other.2.BCVA(Log MAR):After treatment at 1 day,15 days,1 month,3 months and 6 months,mean post-treatment BCVA(converted into Log MAR)of CRVO were 0.98±0.55,0.81±0.55,0.72±0.47,0.54±0.37,0.59±0.37 respectively.BCVA measurements significantly improved compared with that before the treatment 1.09±0.57(P<0.05).After treatment at 1 day,15 days,1 month,3 months and 6 months,mean post-treatment BCVA(converted into Log MAR)of BRVO were 0.80±0.50,0.59±0.45,0.54±0.42,0.53±0.40,0.46±0.36 respectively.BCVA measurements significantly improved compared with that before the treatment 0.95±0.59(P<0.05).3.CMT:Mean CMT of CRVO after treatment at 15 days,1 month,3 months and 6 months were 332.31±85.44,279.69±47.19,282.88±75.82,344.62±124.06.These were significantly reduced when compared to baseline CMT623.50± 181.06(PP<0.05).Mean CMT of BRVO after treatment at 15 days,1 month,3 months and 6 months were 310.00±97.28,268.85±56.27,259.32±44.23,286.12±64.37.These were significantly reduced when compared to baseline CMT523.24±190.06(P<0.05).4.Fundus observation:Fundus photographs showed that hemorrhage of CRVO and BRVO obsorbed significantly,FFA showed a obvious decrease in retinal leakage.5.Injection times: The number of average injection times for CRVO was(3.13±1.41),however,it was(2.97±0.80)for BRVO.6.Complication:Subconjunctival hemorrhage occurred in 5 patients,and corneal epithelium damaged in 2 patients.There were no other serious adverse reaction or complication.7.Predictive factor analysis of visual recovery:FVG of CRVO positively correlated with duration(r=0.541,P < 0.05),baseline BCVA(r=0.591,P < 0.05),patients' age(r=0.751,P<0.05),while the patients' sex(P=0.076),presence or absence of systemic diseases(P=0.951),baseline CMT(P = 0.155)and injection times(P=0.789)had no connection with FVG.FVG of BRVO positively correlated with duration(r=0.498,P<0.05),baseline BCVA(r=0.40,P<0.05),while the patients' sex(P = 0.523),patients' age(P=0.147),presence or absence of systemic diseases(P=0.395),baseline CMT(P = 0.348)and injection times(P=0.36)had no connection with FVG.Conclusions The intravitreal injection of Conbercept in patients with ME secondary to RVO can effectively increase in visual acuity and decrease in central macular thickness and it is safe.Baseline BCVA and duration are the predictive factors of the visual recovery,the better baseline BCVA,the shorter the duration,the better the visual recovery.